Trial Designs for Integrating Novel Therapeutics into the Management of Intermediate-Stage Hepatocellular Carcinoma

Overview

Journal J Hepatocell Carcinoma

Date 2022 Jun 9

PMID 35677350

Authors

Yung-Yeh Su

Yi-Sheng Liu

Chin-Fu Hsiao

Chiun Hsu

Li-Tzong Chen

Affiliations

Soon will be listed here.

Abstract

Intermediate-stage hepatocellular carcinoma (HCC) consists of heterogeneous groups of patients in terms of tumor burden and organ function reserves. Although liver-directed therapy (LDT), including trans-catheter arterial chemoembolization, radiofrequency ablation or even surgical resection, is the recommended frontline treatment modality, intrahepatic and distant failures are common. The recent advances in systemic treatment, notably the introduction of immune checkpoint inhibitor (ICI)-based therapy, have significantly improved the objective tumor response rate, quality of response and overall survival in patients with recurrent and advanced HCC. Whether the combination of systemic treatment and LDT can further improve the outcome of patients with intermediate-stage HCC is currently being extensively evaluated. In this article, the recent clinical trials incorporating different ICI-based combinations with different LDT for intermediate-stage HCC were reviewed focusing on trial design issues, including patient selection, endpoint definition, and biomarker development. The strength and caveats of different combination strategies and novel biomarker development were discussed.

References

Cheng A, Hsu C, Chan S, Choo S, Kudo M . Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J Hepatol. 2020; 72(2):307-319. DOI: 10.1016/j.jhep.2019.09.025. View

Kadalayil L, Benini R, Pallan L, OBeirne J, Marelli L, Yu D . A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol. 2013; 24(10):2565-2570. PMC: 4023407. DOI: 10.1093/annonc/mdt247. View

Yau T, Tang V, Yao T, Fan S, Lo C, Poon R . Development of Hong Kong Liver Cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology. 2014; 146(7):1691-700.e3. DOI: 10.1053/j.gastro.2014.02.032. View

Camma C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F . Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology. 2002; 224(1):47-54. DOI: 10.1148/radiol.2241011262. View

Kudo M, Arizumi T . Transarterial Chemoembolization in Combination with a Molecular Targeted Agent: Lessons Learned from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2). Oncology. 2017; 93 Suppl 1:127-134. DOI: 10.1159/000481243. View

Zhu A, Kang Y, Yen C, Finn R, Galle P, Llovet J . Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019; 20(2):282-296. DOI: 10.1016/S1470-2045(18)30937-9. View

El Fouly A, Ertle J, El Dorry A, Shaker M, Dechene A, Abdella H . In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?. Liver Int. 2014; 35(2):627-35. DOI: 10.1111/liv.12637. View

Singh P, Toom S, Avula A, Kumar V, Rahma O . The Immune Modulation Effect of Locoregional Therapies and Its Potential Synergy with Immunotherapy in Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2020; 7:11-17. PMC: 7022138. DOI: 10.2147/JHC.S187121. View

Hung Y, Lee I, Chi C, Lee R, Liu C, Chiu N . Redefining Tumor Burden in Patients with Intermediate-Stage Hepatocellular Carcinoma: The Seven-Eleven Criteria. Liver Cancer. 2021; 10(6):629-640. PMC: 8647089. DOI: 10.1159/000517393. View

10.

Chen X, Lai L, Ye J, Li L . Downstaging Therapies for Unresectable Hepatocellular Carcinoma Prior to Hepatic Resection: A Systematic Review and Meta-Analysis. Front Oncol. 2021; 11:740762. PMC: 8639517. DOI: 10.3389/fonc.2021.740762. View

11.

Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H . Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2019; 69(8):1492-1501. PMC: 7398460. DOI: 10.1136/gutjnl-2019-318934. View

12.

Hyun M, Lee Y, Kim J, Lee C, Jung Y, Seo Y . Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: A meta-analysis of high-quality studies. Hepatology. 2018; 68(3):977-993. DOI: 10.1002/hep.29883. View

13.

Thommen D, Schumacher T . T Cell Dysfunction in Cancer. Cancer Cell. 2018; 33(4):547-562. PMC: 7116508. DOI: 10.1016/j.ccell.2018.03.012. View

14.

Singal A, Hoshida Y, Pinato D, Marrero J, Nault J, Paradis V . International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma. Gastroenterology. 2021; 160(7):2572-2584. PMC: 8169638. DOI: 10.1053/j.gastro.2021.01.233. View

15.

Zheng Y, Wang T, Tu X, Huang Y, Zhang H, Tan D . Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J Immunother Cancer. 2019; 7(1):193. PMC: 6651993. DOI: 10.1186/s40425-019-0650-9. View

16.

Horikawa M, Miyayama S, Irie T, Kaji T, Arai Y . Development of Conventional Transarterial Chemoembolization for Hepatocellular Carcinomas in Japan: Historical, Strategic, and Technical Review. AJR Am J Roentgenol. 2015; 205(4):764-73. DOI: 10.2214/AJR.15.14825. View

17.

. 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Gut Liver. 2019; 13(3):227-299. PMC: 6529163. DOI: 10.5009/gnl19024. View

18.

Forner A, Llovet J, Bruix J . Hepatocellular carcinoma. Lancet. 2012; 379(9822):1245-55. DOI: 10.1016/S0140-6736(11)61347-0. View

19.

An H, Chon H, Kim C . Peripheral Blood-Based Biomarkers for Immune Checkpoint Inhibitors. Int J Mol Sci. 2021; 22(17). PMC: 8430528. DOI: 10.3390/ijms22179414. View

20.

Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, Imai Y . JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan. Liver Cancer. 2015; 3(3-4):458-68. PMC: 4531423. DOI: 10.1159/000343875. View